PL2187965T3 - Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania - Google Patents
Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowaniaInfo
- Publication number
- PL2187965T3 PL2187965T3 PL08798020T PL08798020T PL2187965T3 PL 2187965 T3 PL2187965 T3 PL 2187965T3 PL 08798020 T PL08798020 T PL 08798020T PL 08798020 T PL08798020 T PL 08798020T PL 2187965 T3 PL2187965 T3 PL 2187965T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- binding ligand
- psma binding
- linker conjugates
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95648907P | 2007-08-17 | 2007-08-17 | |
US7435808P | 2008-06-20 | 2008-06-20 | |
EP08798020.7A EP2187965B1 (en) | 2007-08-17 | 2008-08-15 | Psma binding ligand-linker conjugates and methods for using |
PCT/US2008/073375 WO2009026177A1 (en) | 2007-08-17 | 2008-08-15 | Psma binding ligand-linker conjugates and methods for using |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2187965T3 true PL2187965T3 (pl) | 2020-05-18 |
Family
ID=40378553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08798020T PL2187965T3 (pl) | 2007-08-17 | 2008-08-15 | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
Country Status (16)
Country | Link |
---|---|
US (24) | US9193763B2 (pl) |
EP (6) | EP3388086B1 (pl) |
JP (8) | JP2010536790A (pl) |
CN (2) | CN102014956B (pl) |
AU (1) | AU2008289108C1 (pl) |
CA (1) | CA2696627C (pl) |
DK (1) | DK2187965T3 (pl) |
ES (1) | ES2768224T3 (pl) |
HK (1) | HK1212588A1 (pl) |
HU (1) | HUE047200T2 (pl) |
IL (1) | IL203998A (pl) |
NZ (2) | NZ583931A (pl) |
PL (1) | PL2187965T3 (pl) |
PT (1) | PT2187965T (pl) |
SI (1) | SI2187965T1 (pl) |
WO (1) | WO2009026177A1 (pl) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040015234A (ko) | 2001-05-02 | 2004-02-18 | 펄듀 리서치 파운데이션 | 대식세포 매개된 질환의 치료와 진단 |
US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
ATE412897T1 (de) | 2003-05-30 | 2008-11-15 | Purdue Research Foundation | Diagnoseverfahren für atherosklerose |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
WO2007038346A2 (en) | 2005-09-23 | 2007-04-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
EP2087337A4 (en) | 2006-11-03 | 2010-09-08 | Purdue Research Foundation | METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY |
PL2942065T3 (pl) * | 2006-11-08 | 2018-11-30 | Molecular Insight Pharmaceuticals, Inc. | Heterodimery kwasu glutamowego |
EP2109466B1 (en) | 2007-02-07 | 2014-11-12 | Purdue Research Foundation | Positron emission tomography imaging method |
NZ599239A (en) | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
WO2008148001A2 (en) | 2007-05-25 | 2008-12-04 | Purdue Research Foundation | Method of imaging localized infections |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
GB0718967D0 (en) | 2007-09-28 | 2007-11-07 | Ge Healthcare Ltd | Peptide imaging agents |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
EP2291659B1 (en) * | 2008-05-13 | 2015-09-16 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
CA3035532C (en) * | 2009-03-19 | 2021-10-26 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
US20180009767A9 (en) | 2009-03-19 | 2018-01-11 | The Johns Hopkins University | Psma targeted fluorescent agents for image guided surgery |
US20120183847A1 (en) | 2009-05-19 | 2012-07-19 | Aic Blab | Composite current collector and methods therefor |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
US9951324B2 (en) * | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US20120322741A1 (en) * | 2010-02-25 | 2012-12-20 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
US10363309B2 (en) | 2011-02-04 | 2019-07-30 | Case Western Reserve University | Targeted nanoparticle conjugates |
CN106110332B (zh) | 2011-06-10 | 2018-11-30 | 梅尔莎纳医疗公司 | 蛋白质-聚合物-药物共轭物 |
CA2839195C (en) * | 2011-06-15 | 2021-10-26 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
US8784774B2 (en) | 2011-09-16 | 2014-07-22 | General Electric Company | Labeled molecular imaging agents and methods of use |
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
ES2939836T3 (es) | 2012-07-12 | 2023-04-27 | Hangzhou Dac Biotech Co Ltd | Conjugados de moléculas de unión celular con agentes citotóxicos |
US20140081659A1 (en) | 2012-09-17 | 2014-03-20 | Depuy Orthopaedics, Inc. | Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
SG10201706618UA (en) | 2012-11-15 | 2017-09-28 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
EP2922818B1 (en) | 2012-11-24 | 2018-09-05 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
MX356698B (es) | 2013-02-14 | 2018-06-11 | Bristol Myers Squibb Co | Compuestos de tubulisina, metodos para obtenerlos y uso. |
US11975074B2 (en) | 2013-02-15 | 2024-05-07 | Case Western Reserve University | Photodynamic therapy composition |
US9889199B2 (en) * | 2013-02-15 | 2018-02-13 | Case Western Reserve University | PSMA ligands and uses thereof |
US10207005B2 (en) | 2013-02-15 | 2019-02-19 | Case Western Reserve University | Photodynamic therapy composition |
CN110420333A (zh) * | 2013-03-14 | 2019-11-08 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
US10434194B2 (en) | 2013-06-20 | 2019-10-08 | Case Western Reserve University | PSMA targeted nanobubbles for diagnostic and therapeutic applications |
US10232058B2 (en) | 2013-10-14 | 2019-03-19 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
KR102339240B1 (ko) | 2013-10-15 | 2021-12-15 | 더 스크립스 리서치 인스티튜트 | 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
CA2926698C (en) * | 2013-10-15 | 2021-06-22 | The California Institute For Biomedical Research | Chimeric antigen receptor t cell switches and uses thereof |
EP3495355A1 (en) | 2013-10-18 | 2019-06-12 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US20160367685A1 (en) * | 2013-11-06 | 2016-12-22 | Purdue Research Foundation | Dupa-indenoisoquinoline conjugates |
CN108514646B (zh) * | 2013-11-14 | 2021-07-16 | 恩多塞特公司 | 用于正电子发射断层术的化合物 |
US9468692B2 (en) | 2014-01-23 | 2016-10-18 | General Electric Company | Labeled molecular imaging agents and methods of use |
US9468693B2 (en) | 2014-01-23 | 2016-10-18 | General Electric Company | Labeled molecular imaging agents and methods of use |
ES2960619T3 (es) * | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
EP3140282B1 (en) | 2014-05-06 | 2019-07-10 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
RU2771104C2 (ru) | 2014-05-14 | 2022-04-26 | Таргиммьюн Терапьютикс Аг | Улучшенные полиэтилениминовые полиэтиленгликолевые векторы |
CN104262458B (zh) * | 2014-08-29 | 2017-02-01 | 邵国强 | 一种与psma膜外区靶向性结合的多肽、放射性核素标记多肽及其应用 |
US20170226159A1 (en) * | 2014-09-26 | 2017-08-10 | Kaneka Corporation | Method for producing hydrophobic peptide |
WO2016065145A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | Psma targeted reversed carbamates and methods of use thereof |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
EP3283113A4 (en) | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
WO2016183131A1 (en) | 2015-05-11 | 2016-11-17 | Purdue Research Foundation | Ligand ionophore conjugates |
WO2018094035A2 (en) * | 2016-11-16 | 2018-05-24 | Purdue Research Foundation | Ligand ionophore conjugates |
AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
ES2811347T3 (es) | 2015-08-14 | 2021-03-11 | Endocyte Inc | Método de formación de imágenes con un compuesto quelante |
US10842887B2 (en) | 2015-09-09 | 2020-11-24 | On Target Laboratories, LLC | PSMA-targeted NIR dyes and their uses |
US9808538B2 (en) | 2015-09-09 | 2017-11-07 | On Target Laboratories, LLC | PSMA-targeted NIR dyes and their uses |
WO2017054907A1 (en) * | 2015-09-30 | 2017-04-06 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
CA3002774A1 (en) * | 2015-10-23 | 2017-04-27 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
US10405753B2 (en) * | 2015-11-10 | 2019-09-10 | Intuitive Surgical Operations, Inc. | Pharmaceutical compositions of near IR closed chain, sulfo-cyanine dyes |
CA3006000A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
EP3429637A4 (en) | 2016-03-16 | 2020-03-11 | Endocyte, Inc. | CONJUGATES OF CARBONIC ANHYDRASE IX INHIBITORS AND USES THEREOF |
AU2017234676A1 (en) * | 2016-03-16 | 2018-09-20 | Purdue Research Foundation | Carbonic anhydrase IX targeting agents and methods |
US20170296679A1 (en) | 2016-04-18 | 2017-10-19 | Intuitive Surgical Operations, Inc. | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands |
ES2944610T3 (es) * | 2016-09-09 | 2023-06-22 | On Target Laboratories Llc | Colorantes NIR dirigidos a PSMA y sus usos |
EP3529268A1 (en) | 2016-10-19 | 2019-08-28 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
CN110099682B (zh) | 2016-11-14 | 2023-03-31 | 杭州多禧生物科技有限公司 | 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
KR102085798B1 (ko) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
CN111225688A (zh) * | 2017-08-22 | 2020-06-02 | 普渡研究基金会 | 靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物 |
CN111432844B (zh) | 2017-09-22 | 2023-10-27 | 海德堡医药研究有限责任公司 | 靶向psma的鹅膏蕈碱缀合物 |
EA202091876A1 (ru) | 2018-02-06 | 2020-12-10 | Дзе Джонс Хопкинс Юниверсити | Нацеленные на psma радиогалогенированные соединения мочевины-полиаминокарбоксилатов для радиотерапии рака |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
WO2019246445A1 (en) * | 2018-06-20 | 2019-12-26 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
CN110922450B (zh) * | 2018-09-19 | 2021-11-02 | 薪火炙药(北京)科技有限公司 | Psma激活式抗肿瘤前药cpt-x及其制备方法和应用 |
RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
WO2020108753A1 (en) * | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
EP3893942A4 (en) * | 2018-12-14 | 2022-12-14 | The Johns Hopkins University | PAMAM DENDRIMERS TARGETED FOR PSMA FOR SPECIFIC DELIVERY OF IMAGING, CONTRASTING AND THERAPEUTIC AGENTS |
EP3911336A4 (en) * | 2019-01-18 | 2023-05-10 | Case Western Reserve University | PSMA LIGAND-TARGETED COMPOUNDS AND USES THEREOF |
US20220096669A1 (en) | 2019-01-30 | 2022-03-31 | Technische Universität München | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof |
CN110305186B (zh) * | 2019-06-06 | 2021-02-23 | 原子高科股份有限公司 | ***癌PET诊断试剂68Ga-DOTA-ANCP-PSMA及其制备方法和应用 |
CN110305187B (zh) * | 2019-06-06 | 2021-02-23 | 原子高科股份有限公司 | ***癌PET诊断试剂68Ga-NOTA-ANCP-PSMA及其制备方法和应用 |
WO2021000067A1 (zh) | 2019-06-29 | 2021-01-07 | 杭州多禧生物科技有限公司 | 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法 |
RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
PE20220563A1 (es) * | 2019-07-10 | 2022-04-13 | Cybrexa 2 Inc | Conjugados peptidicos de citotoxinas como terapeuticos |
CN114302744A (zh) | 2019-07-10 | 2022-04-08 | 赛博克萨3公司 | 作为治疗剂的微管靶向剂的肽缀合物 |
CN114945388A (zh) * | 2019-10-23 | 2022-08-26 | 胶原蛋白医疗有限责任公司 | 用于成像和治疗的纤维蛋白结合化合物 |
US20230096410A1 (en) | 2020-03-06 | 2023-03-30 | Sorrento Therapeutics, Inc. | Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells |
WO2021250240A1 (en) | 2020-06-12 | 2021-12-16 | Orano | Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof |
MX2023004101A (es) | 2020-10-08 | 2023-10-11 | Targimmune Therapeutics Ag | Inmunoterapia para el tratamiento de cancer. |
EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
US20230414762A1 (en) * | 2020-11-17 | 2023-12-28 | The Johns Hopkins University | Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma |
CA3212963A1 (en) * | 2021-04-23 | 2022-10-27 | Reinier HERNANDEZ | Psma-targeting ligands with optimal properties for imaging and therapy |
CA3237153A1 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
AU2022388735A1 (en) | 2021-11-09 | 2024-05-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
WO2024100044A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol |
WO2024100046A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100040A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
Family Cites Families (229)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713249A (en) | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
EP0116208B1 (en) | 1982-12-07 | 1988-03-30 | Kyowa Hakko Kogyo Co., Ltd. | Mitomycin analogues |
JPS60255789A (ja) | 1984-06-01 | 1985-12-17 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体,その製造法および抗腫瘍剤 |
US5266333A (en) | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
EP0280741B1 (en) | 1986-08-29 | 1994-12-07 | Kyowa Hakko Kogyo Kabushiki Kaisha | Mitomycin derivatives |
AU634314B2 (en) | 1989-11-13 | 1993-02-18 | Green Cross Corporation, The | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
AU653565B2 (en) | 1990-12-21 | 1994-10-06 | Nikken Corporation | Raw sewage disposal apparatus and prefab for accomodating the same |
US6291196B1 (en) | 1992-01-31 | 2001-09-18 | Research Corporation Technologies, Inc. | Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy |
US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
JP3538221B2 (ja) | 1993-11-19 | 2004-06-14 | 富士写真フイルム株式会社 | 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法 |
US5417982A (en) | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
US5866679A (en) | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
US6946133B1 (en) | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
PT907379E (pt) | 1996-04-01 | 2004-09-30 | Epix Medical Inc | Agentes de contraste bioactivados para imagiologia de diagnostico |
EP0891550A1 (en) | 1996-04-05 | 1999-01-20 | The Johns Hopkins University School Of Medicine | A method of enriching rare cells |
US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US5998362A (en) | 1996-09-12 | 1999-12-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6368598B1 (en) | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
US6177404B1 (en) | 1996-10-15 | 2001-01-23 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
EP2060630B1 (en) | 1997-04-10 | 2012-10-24 | Stichting Katholieke Universiteit University Medical Centre Nijmegen | PCA3, PCA3 genes, and methods of use |
US6127333A (en) | 1997-07-10 | 2000-10-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US20020115596A1 (en) | 1997-10-27 | 2002-08-22 | Merk & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
KR100580137B1 (ko) | 1997-12-02 | 2006-05-16 | 머크 앤드 캄파니 인코포레이티드 | 전립선 암 치료에 유용한 접합체 및 이를 포함하는 약제학적 조성물 |
US20040081659A1 (en) | 1997-12-02 | 2004-04-29 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
ZA9810974B (en) | 1997-12-02 | 1999-06-03 | Merck & Co Inc | Conjugates useful in the treatment of prostate cancer |
CA2322975A1 (en) | 1998-03-03 | 1999-09-10 | Mosaic Technologies | Purification and detection processes using reversible affinity electrophoresis |
US20020103136A1 (en) | 1998-03-05 | 2002-08-01 | Dong-Mei Feng | Conjugates useful in the treatment of prostate cancer |
US6232287B1 (en) | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
ES2629442T3 (es) | 1998-06-01 | 2017-08-09 | Agensys, Inc. | Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos |
US20070020327A1 (en) | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US20030207808A1 (en) | 1999-02-18 | 2003-11-06 | Kinneret Savitzky | Novel nucleic acid and amino acid sequences |
WO2000059930A1 (en) | 1999-04-05 | 2000-10-12 | Merck & Co., Inc. | A method of treating cancer |
US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
US6479470B1 (en) * | 1999-04-28 | 2002-11-12 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase |
AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
US7166573B1 (en) | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
US20040146516A1 (en) | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
US6692724B1 (en) | 1999-10-25 | 2004-02-17 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US6428785B1 (en) | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
CA2391534A1 (en) | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
CZ304942B6 (cs) | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl |
US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
JP4176466B2 (ja) | 2000-10-16 | 2008-11-05 | ギリード・サイエンシズ・インコーポレーテッド | 前立腺特異的膜抗原に対する核酸リガンド |
US20020132983A1 (en) | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
US7468354B2 (en) * | 2000-12-01 | 2008-12-23 | Genspera, Inc. | Tissue specific prodrugs |
WO2002062398A2 (en) | 2001-01-08 | 2002-08-15 | Neorx Corporation | Radioactively labelled conjugates of phosphonates |
EP1363920B1 (en) | 2001-02-07 | 2006-08-23 | Beth Israel Deaconess Medical Center | Modified psma ligands and uses related thereto |
WO2002074345A2 (en) | 2001-03-16 | 2002-09-26 | Johns Hopkins University School Of Medicine | Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules |
ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
KR20040015234A (ko) | 2001-05-02 | 2004-02-18 | 펄듀 리서치 파운데이션 | 대식세포 매개된 질환의 치료와 진단 |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US20040018203A1 (en) | 2001-06-08 | 2004-01-29 | Ira Pastan | Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
EP1410022B1 (en) | 2001-06-21 | 2009-05-06 | GlycoMimetics, Inc. | Detection and treatment of prostate cancer |
EP1409017A4 (en) | 2001-06-25 | 2006-05-24 | Drug Innovation & Design Inc | CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS |
US7755757B2 (en) | 2007-02-14 | 2010-07-13 | Chemimage Corporation | Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging |
US7893223B2 (en) | 2001-07-17 | 2011-02-22 | Bracco Imaging S.P.A. | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy |
DK1567641T3 (da) | 2001-08-24 | 2012-08-27 | Uvic Industry Partnerships Inc | Proaerolysin indeholdende proteaseaktiveringssekvenser og fremgangsmåder til anvendelse til behandling af prostatacancer. |
WO2003024388A2 (en) | 2001-09-20 | 2003-03-27 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |
US20030232760A1 (en) | 2001-09-21 | 2003-12-18 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
DK1434603T3 (da) | 2001-09-28 | 2010-04-26 | Purdue Research Foundation | Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater |
US20030215456A1 (en) | 2001-10-02 | 2003-11-20 | Sui-Long Yao | Method of treating cancer |
US20030133927A1 (en) | 2001-10-10 | 2003-07-17 | Defeo-Jones Deborah | Conjugates useful in the treatment of prostate cancer |
US20040058857A1 (en) | 2001-11-29 | 2004-03-25 | Siu-Long Yao | Method of treating cancer |
US20070031438A1 (en) | 2001-12-10 | 2007-02-08 | Junghans Richard P | Antibodies as chimeric effector cell receptors against tumor antigens |
AU2003205077A1 (en) | 2002-01-10 | 2003-07-30 | Johns Hopkins University | Imaging agents and methods of imaging naaladase of psma |
AU2003217304A1 (en) | 2002-02-28 | 2003-09-16 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
CN1650033A (zh) | 2002-03-07 | 2005-08-03 | 约翰霍普金斯大学医学院 | 针对与癌症相关的表观遗传学沉默基因的基因组筛选 |
US7534580B2 (en) | 2002-05-01 | 2009-05-19 | Ambrilia Biopharma Inc. | PSP94 diagnostic reagents and assays |
DK2260875T3 (da) | 2002-05-06 | 2014-06-30 | Endocyte Inc | Folatreceptor-targetede billeddannelsesmidler |
AU2003243226A1 (en) | 2002-05-15 | 2003-12-02 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
AR040956A1 (es) | 2002-07-31 | 2005-04-27 | Schering Ag | Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico |
JP2004064945A (ja) | 2002-07-31 | 2004-02-26 | Hitachi Koki Co Ltd | 回転体駆動装置 |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
US7749968B2 (en) | 2002-08-05 | 2010-07-06 | The Johns Hopkins University | Peptides for targeting the prostate specific membrane antigen |
WO2004015086A2 (en) | 2002-08-08 | 2004-02-19 | Johns Hopkins University | Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product |
US8487128B2 (en) | 2002-11-26 | 2013-07-16 | Chs Pharma, Inc. | Protection of normal cells |
US7875586B2 (en) | 2002-12-20 | 2011-01-25 | The Johns Hopkins University | Treatment of metastatic colon cancer with b-subunit of shiga toxin |
US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
US20080008649A1 (en) | 2003-01-13 | 2008-01-10 | Bracco Imaging S.P.A. | Gastrin Releasing Peptide Compounds |
DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
US7811564B2 (en) | 2003-01-28 | 2010-10-12 | Proscan Rx Pharma | Prostate cancer diagnosis and treatment |
US7638122B2 (en) | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
EP1603392A2 (en) | 2003-03-07 | 2005-12-14 | The University Of Toledo | Paclitaxel hybrid derivatives |
US20070179100A1 (en) | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
EP1620544B1 (en) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
WO2004096120A2 (en) | 2003-05-01 | 2004-11-11 | Nst Neurosurvival Technologies Ltd. | Compounds that selectively bind to membranes of apoptotic cells |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7172751B2 (en) | 2003-06-13 | 2007-02-06 | Immunomedics, Inc. | D-amino acid peptides |
US7232805B2 (en) | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
WO2005051315A2 (en) | 2003-11-24 | 2005-06-09 | The Regents Of The University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
FR2864546A1 (fr) * | 2003-12-24 | 2005-07-01 | Assist Publ Hopitaux De Paris | Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations |
WO2006051531A2 (en) | 2004-11-09 | 2006-05-18 | Spectrum Dynamics Llc | Radioimaging |
US8586932B2 (en) | 2004-11-09 | 2013-11-19 | Spectrum Dynamics Llc | System and method for radioactive emission measurement |
DE102004004787A1 (de) | 2004-01-30 | 2005-08-18 | Schering Ag | Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP1610818A4 (en) | 2004-03-03 | 2007-09-19 | Millennium Pharm Inc | MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF |
US20070254317A1 (en) | 2004-03-03 | 2007-11-01 | Biomerieux | Method for Detecting the Activatable Free Form of Psa and the Use Thereof for Diagnosing Benign Pathologies of the Prostate and Adenocarcinoma of the Prostate |
ES2311895T3 (es) * | 2004-03-15 | 2009-02-16 | F. Hoffmann-La Roche Ag | El uso de los peptidos tipo bnp y de los peptidos tipo anf para evaluar el riesgo de padecer una complicacion cardio-vascular como frecuencia de sobrecarga del volumen. |
EP1737879B1 (en) | 2004-04-19 | 2012-10-10 | Archemix LLC | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
EP1756166A4 (en) | 2004-04-19 | 2008-08-27 | Proscan Rx Pharma | DIAGNOSIS AND TREATMENT OF PROSTATE CANCER |
US7517903B2 (en) * | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US7740847B2 (en) | 2004-08-04 | 2010-06-22 | Applied Molecular Evolution, Inc. | Variant Fc regions |
WO2006024160A1 (en) | 2004-08-30 | 2006-03-09 | Neuromed Pharmaceuticals Ltd. | Urea derivatives as calcium channel blockers |
US7713944B2 (en) | 2004-10-13 | 2010-05-11 | Isis Pharmaceuticals, Inc. | Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells |
EP1807420B1 (en) | 2004-10-27 | 2010-03-10 | Janssen Pharmaceutica N.V. | Trisubstituted thiophenes as progesterone receptor modulators |
US8423125B2 (en) | 2004-11-09 | 2013-04-16 | Spectrum Dynamics Llc | Radioimaging |
US20060140871A1 (en) | 2004-11-30 | 2006-06-29 | Sillerud Laurel O | Magnetic resonance imaging of prostate cancer |
US7872235B2 (en) | 2005-01-13 | 2011-01-18 | Spectrum Dynamics Llc | Multi-dimensional image reconstruction and analysis for expert-system diagnosis |
US20060155021A1 (en) | 2005-01-13 | 2006-07-13 | Lenges Christian P | Coating compositions containing rheology control agents |
US7741510B2 (en) | 2005-01-13 | 2010-06-22 | E. I. Du Pont De Nemours And Company | Rheology control agents |
WO2006083986A2 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services | Biomarkers for tissue status |
WO2006093991A1 (en) | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
WO2006096754A2 (en) * | 2005-03-07 | 2006-09-14 | Archemix Corp. | Stabilized aptamers to psma and their use as prostate cancer therapeutics |
US8088908B2 (en) | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
KR101068612B1 (ko) | 2005-05-24 | 2011-09-30 | 휴마시스 주식회사 | 유사구조 단백질 비율 측정을 이용한 진단장치 |
DK1891093T3 (da) | 2005-06-14 | 2011-07-11 | Protox Therapeutics Inc | Fremgangsmåde til behandling eller forebyggelse af benign prostatahyperplasi ved anvendelse af modificerede poredannende proteiner |
CA2612762C (en) * | 2005-06-20 | 2013-12-10 | Psma Development Company, Llc | Psma antibody-drug conjugates |
US7403088B2 (en) | 2005-06-29 | 2008-07-22 | Eaton Corporation | Handle apparatus and electrical switching apparartus employing the same |
JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
US20070010014A1 (en) | 2005-07-06 | 2007-01-11 | General Electric Company | Compositions and methods for enhanced delivery to target sites |
EP1909853B1 (en) | 2005-07-19 | 2015-03-18 | Biosensors International Group, Ltd. | Imaging protocols |
CN103893778A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
EP2382995A3 (en) | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
EP2015781A4 (en) | 2005-09-12 | 2009-12-23 | Univ Johns Hopkins | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF |
EP1940841B9 (fr) | 2005-10-07 | 2017-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
US20070134332A1 (en) | 2005-11-21 | 2007-06-14 | Medivas, Llc | Polymer particles for delivery of macromolecules and methods of use |
ES2677555T3 (es) | 2005-11-23 | 2018-08-03 | Ventana Medical Systems, Inc. | Conjugado molecular |
US8258256B2 (en) | 2006-01-05 | 2012-09-04 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
US7635682B2 (en) | 2006-01-06 | 2009-12-22 | Genspera, Inc. | Tumor activated prodrugs |
CA2645809C (en) | 2006-03-14 | 2015-05-26 | Cancer Targeted Technology Llc | Peptidomimetic inhibitors of psma, compounds comprising them, and methods of use |
EP1996716B1 (en) | 2006-03-20 | 2011-05-11 | The Regents of the University of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
US20070225213A1 (en) | 2006-03-23 | 2007-09-27 | Kosak Matthew K | Nucleic acid carriers for delivery of therapeutic agents |
JP2009534309A (ja) | 2006-03-31 | 2009-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | 治療剤の標的化送達のためのシステム |
US20140314864A1 (en) | 2006-03-31 | 2014-10-23 | Massachusetts Institute Of Technology | System for Targeted Delivery of Therapeutic Agents |
US7842280B2 (en) * | 2006-09-06 | 2010-11-30 | Case Western Reserve University | Flexibly labeling peptides |
EP2087337A4 (en) | 2006-11-03 | 2010-09-08 | Purdue Research Foundation | METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY |
PL2942065T3 (pl) | 2006-11-08 | 2018-11-30 | Molecular Insight Pharmaceuticals, Inc. | Heterodimery kwasu glutamowego |
EP2500015A1 (en) | 2006-12-05 | 2012-09-19 | Landec Corporation | Delivery of drugs |
US8507434B2 (en) | 2007-01-03 | 2013-08-13 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
CN103372221B (zh) | 2007-01-11 | 2016-08-24 | 免疫医学股份有限公司 | 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物 |
WO2008094254A2 (en) | 2007-01-26 | 2008-08-07 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
EP2109466B1 (en) | 2007-02-07 | 2014-11-12 | Purdue Research Foundation | Positron emission tomography imaging method |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
NZ599239A (en) | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
JP2010524856A (ja) | 2007-04-10 | 2010-07-22 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ウイルス関連腫瘍の画像化および治療 |
AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
CN104774175B (zh) | 2007-06-26 | 2019-04-16 | 约翰·霍普金斯大学 | 标记的***特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途 |
GB0723246D0 (en) | 2007-07-03 | 2008-01-09 | Barton Michelle | p53 modulator |
WO2009029342A2 (en) | 2007-07-13 | 2009-03-05 | The Johns Hopkins University | B7-dc variants |
AU2008283802A1 (en) | 2007-07-31 | 2009-02-05 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
ES2376175T3 (es) | 2007-09-28 | 2012-03-09 | Bind Biosciences, Inc. | Direccionamiento a células de c�?ncer usando nanopart�?culas. |
JP2011500835A (ja) | 2007-10-25 | 2011-01-06 | エンドサイト,インコーポレイテッド | チューブリシン類および調製プロセス |
US8450290B2 (en) | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
WO2009082606A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
WO2009076434A1 (en) | 2007-12-12 | 2009-06-18 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of integrin vla-4 |
BRPI0906797A2 (pt) | 2008-01-09 | 2015-07-14 | Molecular Insight Pharm Inc | Inibidores de anidrase carbônica ix |
ITTO20080313A1 (it) | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
EP2291659B1 (en) | 2008-05-13 | 2015-09-16 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
SI2774608T1 (sl) | 2008-06-16 | 2020-02-28 | Pfizer Inc. | Polimerni nanodelci, napolnjeni z zdravilom, ter postopki za njihovo pripravo in uporabo |
PL2318366T3 (pl) | 2008-08-01 | 2017-10-31 | Univ Johns Hopkins | Środki wiążące PSMA i ich zastosowania |
WO2010019963A2 (en) | 2008-08-15 | 2010-02-18 | Georgetown University | Na channels, disease, and related assays and compositions |
EP2727606A3 (en) | 2008-09-08 | 2015-09-23 | Psma Development Company, L.L.C. | Compounds for killing psma-expressing, taxane-resistant cancer cells |
EP2166021A1 (en) | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
CA2737496A1 (en) | 2008-09-17 | 2010-03-25 | Endocyte, Inc. | Folate receptor binding conjugates of antifolates |
WO2010045598A2 (en) | 2008-10-17 | 2010-04-22 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
WO2010065906A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
EP2373622A2 (en) | 2008-12-05 | 2011-10-12 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
EP2398504B1 (en) | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
WO2010107909A2 (en) | 2009-03-17 | 2010-09-23 | The Johns Hopkins University | Methods and compositions for the detection of cancer |
CA3035532C (en) | 2009-03-19 | 2021-10-26 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
WO2010147965A2 (en) | 2009-06-15 | 2010-12-23 | Molecular Insight Pharmaceuticals, Inc. | Process for production of heterodimers of glutamic acid |
JP2013501224A (ja) | 2009-07-31 | 2013-01-10 | エンドサイト,インク. | 葉酸を標的とした診断及び処置 |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
US8313128B2 (en) | 2009-08-20 | 2012-11-20 | Rhoost, Llc. | Safety locking mechanism for doors |
WO2011031517A1 (en) | 2009-08-27 | 2011-03-17 | Nuclea Biotechnologies, LLC | Method and assay for determining fas expression |
MX354143B (es) | 2009-12-02 | 2018-02-14 | Imaginab Inc | Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso. |
EP2509634B1 (en) | 2009-12-11 | 2019-03-06 | Pfizer Inc | Stable formulations for lyophilizing therapeutic particles |
US8987319B2 (en) | 2010-02-04 | 2015-03-24 | Radius Health, Inc. | Selective androgen receptor modulators |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US20120322741A1 (en) | 2010-02-25 | 2012-12-20 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
CN101863924B (zh) | 2010-05-17 | 2012-06-27 | 北京师范大学 | 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法 |
CA2819850C (en) | 2010-12-06 | 2019-07-23 | John W. Babich | Psma-targeted dendrimers |
US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
EP2739316B1 (en) | 2011-08-05 | 2019-04-10 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
WO2013028664A1 (en) | 2011-08-22 | 2013-02-28 | Siemens Medical Solutions Usa, Inc. | Psma imaging agents |
WO2013130776A1 (en) | 2012-02-29 | 2013-09-06 | Purdue Research Foundation | Folate receptor alpha binding ligands |
US20140107316A1 (en) | 2012-10-16 | 2014-04-17 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
SG10201706618UA (en) | 2012-11-15 | 2017-09-28 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
US20140154702A1 (en) | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
WO2014096365A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
MY172519A (en) | 2012-12-28 | 2019-11-28 | Tarveda Therapeutics Inc | Solid polymeric controlled release nanoparticle |
US9889199B2 (en) | 2013-02-15 | 2018-02-13 | Case Western Reserve University | PSMA ligands and uses thereof |
US20140249315A1 (en) | 2013-03-01 | 2014-09-04 | Endocyte, Inc. | Processes for preparing tubulysins |
US10406246B2 (en) | 2013-10-17 | 2019-09-10 | Deutsches Kresbsforschungszentrum | Double-labeled probe for molecular imaging and use thereof |
EP3495355A1 (en) | 2013-10-18 | 2019-06-12 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US20150110814A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
CN108514646B (zh) | 2013-11-14 | 2021-07-16 | 恩多塞特公司 | 用于正电子发射断层术的化合物 |
EP3140282B1 (en) | 2014-05-06 | 2019-07-10 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
US9956305B2 (en) | 2014-09-08 | 2018-05-01 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer |
WO2016183131A1 (en) * | 2015-05-11 | 2016-11-17 | Purdue Research Foundation | Ligand ionophore conjugates |
US10842887B2 (en) * | 2015-09-09 | 2020-11-24 | On Target Laboratories, LLC | PSMA-targeted NIR dyes and their uses |
US9808538B2 (en) * | 2015-09-09 | 2017-11-07 | On Target Laboratories, LLC | PSMA-targeted NIR dyes and their uses |
FR3043970B1 (fr) | 2015-11-25 | 2019-06-21 | Medtech Sa | Systeme mecanique de stabilisation au sol pour vehicules a roulettes |
-
2008
- 2008-08-15 PL PL08798020T patent/PL2187965T3/pl unknown
- 2008-08-15 SI SI200832106T patent/SI2187965T1/sl unknown
- 2008-08-15 NZ NZ583931A patent/NZ583931A/en unknown
- 2008-08-15 EP EP18175078.7A patent/EP3388086B1/en active Active
- 2008-08-15 WO PCT/US2008/073375 patent/WO2009026177A1/en active Application Filing
- 2008-08-15 HU HUE08798020A patent/HUE047200T2/hu unknown
- 2008-08-15 EP EP08798020.7A patent/EP2187965B1/en not_active Revoked
- 2008-08-15 CN CN200880111794.1A patent/CN102014956B/zh active Active
- 2008-08-15 EP EP20216457.0A patent/EP3858347A3/en active Pending
- 2008-08-15 CN CN201510221167.5A patent/CN104873982A/zh active Pending
- 2008-08-15 JP JP2010521210A patent/JP2010536790A/ja active Pending
- 2008-08-15 NZ NZ600085A patent/NZ600085A/en unknown
- 2008-08-15 EP EP20196752.8A patent/EP3838298A3/en active Pending
- 2008-08-15 PT PT87980207T patent/PT2187965T/pt unknown
- 2008-08-15 US US12/673,931 patent/US9193763B2/en active Active
- 2008-08-15 DK DK08798020.7T patent/DK2187965T3/da active
- 2008-08-15 EP EP20196755.1A patent/EP3831380A3/en active Pending
- 2008-08-15 CA CA2696627A patent/CA2696627C/en active Active
- 2008-08-15 ES ES08798020T patent/ES2768224T3/es active Active
- 2008-08-15 AU AU2008289108A patent/AU2008289108C1/en active Active
- 2008-08-15 EP EP19188077.2A patent/EP3656403B1/en active Active
-
2010
- 2010-02-17 IL IL203998A patent/IL203998A/en active IP Right Grant
-
2013
- 2013-03-14 US US13/826,079 patent/US8907058B2/en active Active
-
2014
- 2014-06-18 JP JP2014125603A patent/JP5902237B2/ja active Active
-
2015
- 2015-11-23 US US14/794,482 patent/US10046054B2/en active Active
-
2016
- 2016-01-15 HK HK16100437.3A patent/HK1212588A1/zh unknown
- 2016-03-09 JP JP2016046076A patent/JP2016153410A/ja active Pending
-
2017
- 2017-05-26 US US15/606,913 patent/US10406240B2/en active Active
- 2017-11-21 JP JP2017223872A patent/JP6596479B2/ja active Active
-
2018
- 2018-04-20 US US15/959,110 patent/US10624969B2/en active Active
- 2018-05-25 US US15/990,083 patent/US10517956B2/en active Active
- 2018-05-25 JP JP2018100343A patent/JP6625690B2/ja active Active
- 2018-05-25 US US15/990,136 patent/US10646581B2/en active Active
- 2018-05-25 US US15/990,152 patent/US10828282B2/en active Active
- 2018-05-25 US US15/990,111 patent/US10485878B2/en active Active
- 2018-05-25 US US15/990,144 patent/US10624971B2/en active Active
- 2018-05-25 US US15/990,095 patent/US10624970B2/en active Active
- 2018-06-04 US US15/997,451 patent/US10517957B2/en active Active
-
2019
- 2019-07-10 US US16/507,713 patent/US11298341B2/en active Active
- 2019-09-30 JP JP2019179190A patent/JP6838118B2/ja active Active
- 2019-12-17 US US16/717,753 patent/US20200188523A1/en not_active Abandoned
-
2020
- 2020-01-22 US US16/749,827 patent/US11083710B2/en active Active
- 2020-01-22 US US16/749,896 patent/US20200297701A1/en not_active Abandoned
- 2020-05-07 US US16/869,268 patent/US11504357B2/en active Active
- 2020-10-30 US US17/086,063 patent/US11717514B2/en active Active
-
2021
- 2021-02-10 JP JP2021019732A patent/JP7079355B2/ja active Active
- 2021-06-25 US US17/358,726 patent/US20220096445A1/en active Pending
- 2021-06-25 US US17/359,277 patent/US11369590B2/en active Active
- 2021-06-25 US US17/359,314 patent/US11318121B2/en active Active
-
2022
- 2022-01-11 US US17/573,304 patent/US20230000836A1/en active Pending
- 2022-05-19 JP JP2022082105A patent/JP2022110118A/ja active Pending
- 2022-11-21 US US17/991,013 patent/US20230293497A1/en active Pending
-
2023
- 2023-03-09 US US18/181,487 patent/US20230346752A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212588A1 (zh) | 結合配體-接頭綴合物及其使用方法 | |
HRP20181902T1 (hr) | Međuvrsno specifična vezujuća domena | |
HK1217203A1 (zh) | 白介素- 的結合成員 | |
IL234081B (en) | Antibody binds cd3–epsilon in different species | |
GB2496951C (en) | Binders | |
GB2449354B (en) | Binding protein | |
HK1148329A1 (zh) | 捆綁裝置 | |
IL200845A0 (en) | Oligomer-opoid agonist conjugates | |
EP2202088A4 (en) | BINDING DEVICE | |
GB0702183D0 (en) | Pathogen binding | |
HK1129349A1 (en) | Folder binding device | |
EP2108522A4 (en) | BINDER | |
IL199718A0 (en) | Peptide-complement conjugates | |
GB0621279D0 (en) | Binding site | |
GB0706502D0 (en) | Binding device | |
GB2433914B (en) | Book binding | |
GB0712532D0 (en) | Binders | |
GB0713727D0 (en) | Book | |
GB0711244D0 (en) | Binding molecules | |
GB0603219D0 (en) | Binders | |
GB0704842D0 (en) | Binding polypeptides |